Dingxie J. Liu

No. 800, Xiangyin Rd
Shanghai, 200433, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 22 publications

Expression of NOTCH1, NOTCH4, HLA-DMA and HLA-DRA is synergistically associated with T cell exclusion, immune checkpoint blockade efficacy and recurrence risk in ER-negative breast cancer.

Expression of NOTCH1, NOTCH4, HLA-DMA and HLA-DRA is synergistically associated with T cell exclusion, immune checkpoint blockade efficacy and recurrence risk in ER-negative breast cancer.

Journal: Cellular oncology (Dordrecht, Netherlands)

Published: April 20, 2022

Mutations in KMT2C, BCOR and KDM5C Predict Response to Immune Checkpoint Blockade Therapy in Non-Small Cell Lung Cancer.

Mutations in KMT2C, BCOR and KDM5C Predict Response to Immune Checkpoint Blockade Therapy in Non-Small Cell Lung Cancer.

Journal: Cancers

Published: April 15, 2022

ZBED2 expression enhances interferon signaling and predicts better survival of estrogen receptor-negative breast cancer patients.

ZBED2 expression enhances interferon signaling and predicts better survival of estrogen receptor-negative breast cancer patients.

Journal: Cancer communications (London, England)

Published: October 30, 2021

A Novel Metabolic Reprogramming Strategy for the Treatment of Diabetes-Associated Breast Cancer.

A Novel Metabolic Reprogramming Strategy for the Treatment of Diabetes-Associated Breast Cancer.

Journal: Advanced science (Weinheim, Baden-Wurttemberg, Germany)

Published: June 01, 2021

Basal-like breast cancer with low TGFβ and high TNFα pathway activity is rich in activated memory CD4 T cells and has a good prognosis.

Basal-like breast cancer with low TGFβ and high TNFα pathway activity is rich in activated memory CD4 T cells and has a good prognosis.

Journal: International journal of biological sciences

Published: November 24, 2020

AR pathway activity correlates with AR expression in a HER2-dependent manner and serves as a better prognostic factor in breast cancer.

AR pathway activity correlates with AR expression in a HER2-dependent manner and serves as a better prognostic factor in breast cancer.

Journal: Cellular oncology (Dordrecht, Netherlands)

Published: December 30, 2019

Identification of a prognostic LncRNA signature for ER-positive, ER-negative and triple-negative breast cancers.

Identification of a prognostic LncRNA signature for ER-positive, ER-negative and triple-negative breast cancers.

Journal: Breast cancer research and treatment

Published: November 01, 2019

BRAF/MEK Pathway is Associated With Breast Cancer in ER-dependent Mode and Improves ER Status-based Cancer Recurrence Prediction.

BRAF/MEK Pathway is Associated With Breast Cancer in ER-dependent Mode and Improves ER Status-based Cancer Recurrence Prediction.

Journal: Clinical breast cancer

Published: June 29, 2019

Association of an anaplastic lymphoma kinase pathway signature with cell de-differentiation, neoadjuvant chemotherapy response, and recurrence risk in breast cancer.

Association of an anaplastic lymphoma kinase pathway signature with cell de-differentiation, neoadjuvant chemotherapy response, and recurrence risk in breast cancer.

Journal: Cancer communications (London, England)

Published: January 01, 2019

Concomitant dysregulation of the estrogen receptor and BRAF/MEK signaling pathways is common in colorectal cancer and predicts a worse prognosis.

Concomitant dysregulation of the estrogen receptor and BRAF/MEK signaling pathways is common in colorectal cancer and predicts a worse prognosis.

Journal: Cellular oncology (Dordrecht, Netherlands)

Published: December 26, 2018

Gene signatures of estrogen and progesterone receptor pathways predict the prognosis of colorectal cancer.

Gene signatures of estrogen and progesterone receptor pathways predict the prognosis of colorectal cancer.

Journal: The FEBS journal

Published: May 06, 2016

REC8 is a novel tumor suppressor gene epigenetically robustly targeted by the PI3K pathway in thyroid cancer.

REC8 is a novel tumor suppressor gene epigenetically robustly targeted by the PI3K pathway in thyroid cancer.

Journal: Oncotarget

Published: July 16, 2015

Showing 1-12 of 22

Last Updated: 09/26/2026